[go: up one dir, main page]

CU23093A1 - Composición vacunal que comprende interleucina-15 (il-15) - Google Patents

Composición vacunal que comprende interleucina-15 (il-15)

Info

Publication number
CU23093A1
CU23093A1 CU20020218A CU20020218A CU23093A1 CU 23093 A1 CU23093 A1 CU 23093A1 CU 20020218 A CU20020218 A CU 20020218A CU 20020218 A CU20020218 A CU 20020218A CU 23093 A1 CU23093 A1 CU 23093A1
Authority
CU
Cuba
Prior art keywords
vaccine composition
vaccine
interleucine
overexpression
composition including
Prior art date
Application number
CU20020218A
Other languages
English (en)
Inventor
Castillo Jose Rafael Martinez
Alfonso Armando Alex Rodriguez
Diaz Yanelis Morera
Soria Alejandro Moro
Rodriguez Silvio Ernesto Perea
Rodriguez Ricardo Silva
Perez Haydee Geronimo
Savio Alicia Santos
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20020218A priority Critical patent/CU23093A1/es
Priority to ARP030103644A priority patent/AR041540A1/es
Priority to AT03757652T priority patent/ATE419004T1/de
Priority to PCT/CU2003/000010 priority patent/WO2004032956A1/es
Priority to AU2003273725A priority patent/AU2003273725A1/en
Priority to JP2004542155A priority patent/JP2006507260A/ja
Priority to DE60325619T priority patent/DE60325619D1/de
Priority to EP03757652A priority patent/EP1550457B1/en
Priority to KR1020057005342A priority patent/KR20050074957A/ko
Priority to SI200331536T priority patent/SI1550457T1/sl
Priority to CNB2003801011323A priority patent/CN100540050C/zh
Priority to ES03757652T priority patent/ES2319981T3/es
Priority to US10/529,923 priority patent/US8007776B2/en
Publication of CU23093A1 publication Critical patent/CU23093A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composición vacunal con IL-15 para la inmunización activa en el tratamiento de enfermedades relacionadas con la sobre expresión de esta citocina. El objetivo técnico que se persigue con esta invención es inhibir la actividad de la IL-15 mediante el desarrollo de una vacuna terapéutica que genere anticuerpos neutralizantes de la IL-15 en el individuo inmunizado. En esta composición vacunal la IL-15 puede presentarse sola o acoplada a una proteína portadora (carrier) tal como la P64K y un adyuvante tal como el hidróxido de aluminio. La invención se relaciona además con el uso de esta vacuna en el tratamiento de la Artritis reumatoide y otras enfermedades relacionadas con la sobre expresión de la IL-15, o donde esta citocina actúa como un factor de crecimiento como es el caso de las leucemias.
CU20020218A 2002-10-09 2002-10-09 Composición vacunal que comprende interleucina-15 (il-15) CU23093A1 (es)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CU20020218A CU23093A1 (es) 2002-10-09 2002-10-09 Composición vacunal que comprende interleucina-15 (il-15)
ARP030103644A AR041540A1 (es) 2002-10-09 2003-10-07 Composicion vacunal que comprende interleucina 15 (il-15)
AT03757652T ATE419004T1 (de) 2002-10-09 2003-10-08 Vakzine-zusammensetzung mit interleukin-15 (il- 15)
PCT/CU2003/000010 WO2004032956A1 (es) 2002-10-09 2003-10-08 Composición vacunal que comprende interleucina-15 (il-15)
AU2003273725A AU2003273725A1 (en) 2002-10-09 2003-10-08 Vaccine composition comprising interleukin-15 (il-15)
JP2004542155A JP2006507260A (ja) 2002-10-09 2003-10-08 インターロイキン−１５（ｉｌ−１５）を含むワクチン組成物
DE60325619T DE60325619D1 (de) 2002-10-09 2003-10-08 Vakzine-zusammensetzung mit interleukin-15 (il-15)
EP03757652A EP1550457B1 (en) 2002-10-09 2003-10-08 Vaccine composition comprising interleukin-15 (il-15)
KR1020057005342A KR20050074957A (ko) 2002-10-09 2003-10-08 인터류이킨-15를 포함하는 백신 조성물
SI200331536T SI1550457T1 (sl) 2002-10-09 2003-10-08 Sestavek vakcine, ki obsega interlevkin-15 (IL-15)
CNB2003801011323A CN100540050C (zh) 2002-10-09 2003-10-08 含有白细胞介素-15(il-15)的疫苗组合物
ES03757652T ES2319981T3 (es) 2002-10-09 2003-10-08 Composicion de vacuna que comprende interleucina-15 (il-15).
US10/529,923 US8007776B2 (en) 2002-10-09 2003-10-08 Vaccine composition comprising interleukin-15 (IL-15)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20020218A CU23093A1 (es) 2002-10-09 2002-10-09 Composición vacunal que comprende interleucina-15 (il-15)

Publications (1)

Publication Number Publication Date
CU23093A1 true CU23093A1 (es) 2005-10-19

Family

ID=32078034

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20020218A CU23093A1 (es) 2002-10-09 2002-10-09 Composición vacunal que comprende interleucina-15 (il-15)

Country Status (13)

Country Link
US (1) US8007776B2 (es)
EP (1) EP1550457B1 (es)
JP (1) JP2006507260A (es)
KR (1) KR20050074957A (es)
CN (1) CN100540050C (es)
AR (1) AR041540A1 (es)
AT (1) ATE419004T1 (es)
AU (1) AU2003273725A1 (es)
CU (1) CU23093A1 (es)
DE (1) DE60325619D1 (es)
ES (1) ES2319981T3 (es)
SI (1) SI1550457T1 (es)
WO (1) WO2004032956A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23472A1 (es) * 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech Péptido antagonista de la interleucina-15
US20110123484A1 (en) * 2005-07-07 2011-05-26 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Resource Methods and compositions for treating fus1 related disorders
SE532249C2 (sv) * 2006-11-13 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av IL-18 för behandling av olika inflammatoriska sjukdomar genom vaccinering
CN102266551B (zh) * 2011-06-27 2015-05-13 刘永庆 可用于治疗人或动物免疫相关性疾病的白介素-4治疗性疫苗
CU24546B1 (es) * 2016-12-30 2021-09-07 Ct Ingenieria Genetica Biotecnologia Composición vacunal que comprende un mutante de la interleucina-15 humana
US11058725B2 (en) 2019-09-10 2021-07-13 Obsidian Therapeutics, Inc. CA2 compositions and methods for tunable regulation
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
DE69425906T2 (de) * 1994-04-06 2001-03-29 Immunex Corp., Seattle Interleukin-15
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
ES2187946T3 (es) * 1997-02-21 2003-06-16 Vlaams Interuniv Inst Biotech Uso de interleucina-15.
GB9814892D0 (en) * 1998-07-10 1998-09-09 Kennedy Rheumatology Inst Treatment of celiac disease

Also Published As

Publication number Publication date
KR20050074957A (ko) 2005-07-19
ATE419004T1 (de) 2009-01-15
US20060182713A1 (en) 2006-08-17
DE60325619D1 (de) 2009-02-12
CN100540050C (zh) 2009-09-16
WO2004032956A1 (es) 2004-04-22
AU2003273725A1 (en) 2004-05-04
ES2319981T3 (es) 2009-05-18
CN1703239A (zh) 2005-11-30
AR041540A1 (es) 2005-05-18
JP2006507260A (ja) 2006-03-02
US8007776B2 (en) 2011-08-30
EP1550457A1 (en) 2005-07-06
EP1550457B1 (en) 2008-12-31
SI1550457T1 (sl) 2009-06-30

Similar Documents

Publication Publication Date Title
BRPI0412202A (pt) emplastro para imunização tendo um arranjo de microprojeções, e método
AR054426A1 (es) Uso de un inhibidor de la dimerizacion de receptores tirosina quinasas her para la manufactura de un medicamento para alargar el tiempo hasta l a progresion de la enfermedad o la supervivencia de los pacientes de cancer
CY1110783T1 (el) Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων
AR088110A2 (es) Uso de un inmunoconjugado que comprende un anticuerpo anti-erbb2 para la manufactura de un medicamento
BR0309492A (pt) Uso de pelo menos um álcool ramificado alcoxilado
BRPI0518104A (pt) métodos de tratamento de cáncer, artigo industrializado e uso de um anticorpo her
PE20081635A1 (es) Agentes para suprimir la reaccion de rechazo cronica
ECSP066683A (es) Vacuna para mejorar el crecimiento, a base de epítopes neutralizantes
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
CY1114912T1 (el) Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστου
CU23093A1 (es) Composición vacunal que comprende interleucina-15 (il-15)
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
IL240695B2 (en) Nme inhibitors and methods of using nme inhibitors
KR20220005082A (ko) 탈모 및 탈모 관련 문제증상 치료를 위한 감마-c-사이토카인 신호전달 효과 조절
UY27961A1 (es) Compuestos antiinflamatorios de di y trifluoro-triazolo-piridinas
MX2021005485A (es) Agonista del receptor de interleuquina-15 de accion prolongada con otro agente farmacologicamente activo.
ES2118058T3 (es) Factor de crecimiento de las celulas t.
ATE419008T1 (de) Adjuvante zusammensetzung und anwendungsverfahren dafür
IL144265A0 (en) Use of antibodies for the vaccination against cancer
UY27058A1 (es) Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
CO2022013055A2 (es) Tafoxiparina para el tratamiento de la preeclampsia
BR0316132A (pt) Método para estimular o crescimento de cabelo utilizando benzopiranos
CY1116914T1 (el) ΧΡΗΣΗ ΒΕΝΖΥΔΑΜΙΝΗΣ ΣΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΑΣΘΕΝΕΙΩΝ ΕΞΑΡΤΩΜΕΝΩΝ ΑΠΟ ΤΗΝ p40
CL2024002103A1 (es) Métodos para tratar amiloidosis al